|
09 Sep 2025 |
Biocon
|
Consensus Share Price Target
|
364.50 |
380.11 |
- |
4.28 |
buy
|
|
|
|
|
15 Feb 2023
|
Biocon
|
Motilal Oswal
|
364.50
|
250.00
|
238.10
(53.09%)
|
Target met |
Neutral
|
|
|
|
|
16 Nov 2022
|
Biocon
|
ICICI Securities Limited
|
364.50
|
362.00
|
284.40
(28.16%)
|
|
Buy
|
|
|
Biocon Limited’s (Biocon) Q2FY23 performance was ahead of our estimates led by
better than expected results in the generics and research services. Generics revenue was up 17.5% YoY to Rs6.2bn while Research services delivered a robust growth of 25.9% YoY to Rs.7.7bn.
|
|
15 Nov 2022
|
Biocon
|
ICICI Direct
|
364.50
|
290.00
|
283.85
(28.41%)
|
Target met |
Hold
|
|
|
|
|
15 Nov 2022
|
Biocon
|
Axis Direct
|
364.50
|
310.00
|
283.85
(28.41%)
|
|
Hold
|
|
|
Management indicated that R&D costs will increase in the upcoming quarters which may pose threat to the current margins of the company. We, therefore, recommend a HOLD rating on the stock with a TP of Rs 310/share.
|
|
10 Aug 2022
|
Biocon
|
Geojit BNP Paribas
|
364.50
|
340.00
|
311.15
(17.15%)
|
|
Hold
|
|
|
|
|
28 Jul 2022
|
Biocon
|
ICICI Direct
|
364.50
|
320.00
|
306.75
(18.83%)
|
|
Hold
|
|
|
|
|
30 Apr 2022
|
Biocon
|
ICICI Direct
|
364.50
|
380.00
|
368.45
(-1.07%)
|
|
Hold
|
|
|
|
|
29 Apr 2022
|
Biocon
|
Axis Direct
|
364.50
|
420.00
|
368.45
(-1.07%)
|
|
Buy
|
|
|
We recommend a BUY rating on the stock with a Target Price of Rs 420.
|
|
04 Mar 2022
|
Biocon
|
ICICI Securities Limited
|
364.50
|
390.00
|
328.20
(11.06%)
|
|
Hold
|
|
|
Biosimilar US pipeline: (approvals - Pegfilgrastim, Trastuzumab, Glargine, Adalimumab); filed - Aspart and Bevacizumab Revenue breakup FY21: biosimilars (37%), generics (31%), CRAMS (29%)...
|
|
28 Feb 2022
|
Biocon
|
Motilal Oswal
|
364.50
|
385.00
|
344.85
(5.70%)
|
Target met |
Neutral
|
|
|
BBL (a subsidiary of BIOS) will acquire Viatris' Biosimilar business to create a vertically integrated company in the Biologics segment. With this acquisition, BBL will acquire the commercial infrastructure in developed/emerging markets, rights for all Biosimilar assets (including the in-licensed portfolio), and the option to acquire rights of bAflibercept. This also fills BBL's gap in regulatory development and supply chain management of Biosimilars in the developed market. The management pegs the estimated revenue/EBITDA of Viatris'...
|